Joseph P. Hendrick

Intra Cellular Therapies (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index6.6kcitations55works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA and protein synthesis mechanisms(10), Mitochondrial Function and Pathology(8), Phosphodiesterase function and regulation(8), Neuroscience and Neuropharmacology Research(6), Metabolism and Genetic Disorders(6)

Publications55 total

Inhibition of calcium-calmodulin-dependent phosphodiesterase (PDE1) suppresses inflammatory responses
Molecular and Cellular Neuroscience·2019· 37 citedOpen Access
ITI-214, A Novel Phosphodiesterase I Inhibitor for the Treatment of Parkinson’s Disease: Results from A Phase I/II Clinical Study (P2.8-051)
Neurology·2019· 6 cited
Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition
Circulation·2018· 66 citedOpen Access
S81. Unique Pharmacology and Clinical Evidence Supporting the Antidepressant Therapeutic Potential of Lumateperone
Biological Psychiatry·2018· 1 cited
The presynaptic D2 partial agonist lumateperone acts as a postsynaptic D2 antagonist
Matters·2018· 8 cited
[P4–587]: SUPPRESSION OF CNS INFLAMMATION BY PHOSPHODIESTERASE‐1 (PDE1) INHIBITORS: TOWARD NEW TREATMENTS FOR NEURODEGENERATIVE DISEASES
Alzheimer s & Dementia·2017· 1 citedOpen Access
Phosphodiesterase 1: A Unique Drug Target for Degenerative Diseases and Cognitive Dysfunction
Advances in neurobiology·2017· 27 cited
Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats
Psychopharmacology·2016· 59 citedOpen Access
Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases
Journal of Medicinal Chemistry·2016· 79 citedOpen Access
Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
Psychopharmacology·2014· 280 citedOpen Access
Poster #S176 UNIQUELY TARGETED MOLECULAR THERAPEUTIC FOR SCHIZOPHRENIA: CHARACTERIZATION OF ITI-007 IN VITRO AND IN VIVO ANIMAL MODELS
Schizophrenia Research·2014
Poster #S78 THE NOVEL PHARMACOLOGY OF ITI-007 IS ENHANCED AND EXTENDED BY ITS METABOLIC BACK CONVERSION FROM IC200131
Schizophrenia Research·2014· 6 cited
The Role of Phosphodiesterases in Dopamine Systems governing Motivated Behavior
2014
Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders
Journal of Medicinal Chemistry·2014· 94 citedOpen Access
Muscarinic receptors acting at pre- and post-synaptic sites differentially regulate dopamine/DARPP-32 signaling in striatonigral and striatopallidal neurons
Neuropharmacology·2012· 20 cited
Development of phosphodiesterase-1 inhibitors for negative symptoms of schizophrenia
International Clinical Psychopharmacology·2011
ITI-007
International Clinical Psychopharmacology·2011· 1 cited
Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease
Nature·2010· 322 citedOpen Access
Nerve agent exposure elicits site-specific changes in protein phosphorylation in mouse brain
Brain Research·2010· 23 cited
ENHANCEMENT OF COGNITION IN SCHIZOPHRENIA VIA INHIBITION OF PHOSPHODIESTERASE-1B AND POTENTIATION OF DOPAMINE D1 RECEPTOR SIGNALING
Schizophrenia Research·2010· 1 cited
page 1 of 3Next →

Frequent Co-authors

Gretchen L. Snyder(17), Lawrence P. Wennogle(16), Robert E. Davis(13), Kimberly E. Vanover(9), Sharon Mates(9), Joan A. Steitz(6), Hongwen Zhu(6), F. Ulrich Hartl(5), Jutta Rinke(5), František Kalousek(5), Allen A. Fienberg(5), William Wickner(4), Sandra L. Wolin(4), M R Lerner(4), Leah Rosenberg(4), Wei Yao(4), Santanu Mondal(3), Peng Li(3), Paul Greengard(3), Diane B. Miller(3)